Obstetrics & Gynecology Doctors in Malvern, PA Accepting Medicare

6 Obstetrics & Gynecology doctors found. Showing 1 - 6

Rachel L. Kramer, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 325 Central Ave, Suite 100, Malvern, PA 19355 Phone: 610-251-9433    Fax: 610-251-9539

Dr. Anthony Delconte Iii, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 40 Valley Stream Pkwy, Malvern, PA 19355 Phone: 484-321-5959

Dr. Wendy S Manko, DO Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 325 Central Ave, Suite 100, Malvern, PA 19355 Phone: 610-251-9433    Fax: 610-251-2580

Dr. Joseph Salvatore Ferroni, M.D. Obstetrics & Gynecology - Gynecology Medicare: Not Enrolled in Medicare Practice Location: 462 E King Rd, Malvern, PA 19355 Phone: 610-725-8787    Fax: 610-725-9234

Kim Einhorn, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 325 Central Ave, Suite 100, Malvern, PA 19355 Phone: 610-251-9433    Fax: 610-251-9539

Janine M Barsoum, DO Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 325 Central Ave, Suite 100, Malvern, PA 19355 Phone: 106-251-9433    Fax: 610-251-9539

News Archive

Novavax announces new data from trivalent seasonal influenza VLP vaccine study

Novavax, Inc. announced today new data from a clinical study that began in May of 2009 among healthy adults 18 to 49 years of age with Novavax's trivalent seasonal influenza Virus-like Particle (VLP) vaccine. The vaccine matched the influenza strains recommended for the 2008-2009 influenza season including H1N1 A/Brisbane/59/2007, H3N2 A/Brisbane/10/2007, and B/Florida/04/2006 strains.

MAP Pharmaceuticals to present new analyses from LEVADEX Phase 3 trial for acute migraine at 52nd AHS

MAP Pharmaceuticals, Inc. today announced that the Company will present new analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy. The post hoc analyses will be presented at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California.

RegeneRx to begin RGN-259 Phase 3 trials for treatment of neurotrophic keratopathy

RegeneRx Biopharmaceuticals, Inc. ("the Company" or "RegeneRx") today announced that it met with the FDA in September and as a result of the meeting may begin Phase 3 to evaluate RGN-259 preservative-free eye drops for the treatment of patients with neurotrophic keratopathy (NK), an orphan disease of the cornea.

Study aims to achieve early detection of heart disease

With the month of February designated as Heart Health Month, physician-researchers in the Division of Cardiology at the Los Angeles Biomedical Research Institute (LA BioMed) - Dr. Matthew Budoff and Dr. Ronald Oudiz - continue to pave the way with their efforts to develop treatments and therapies for conditions affecting the heart, and to help improve overall heart health.

Doctors warm to single-payer health care

Single-payer health care is still a controversial idea in the U.S., but a majority of physicians are moving to support it, a new survey finds.

Read more Medical News

› Verified 3 days ago